Overall market situation:
Sentiment during the last trading session in Europe this week is mixed. The German DAX is currently losing 0.8%, while the British FTSE100 is adding 0.85%. Volatility remains high, which indicates that the pressure from the US-China trade war is still creating uncertain ground for future stock market behavior. For this reason, any new comments on this issue may increase the dynamics of changes in the prices of financial instruments in the near future.
Distribution of today’s rates of return of companies from Europe. Source: xStation
The German DE40 index is losing 1.7% today on an intraday basis. The key element in analyzing the further, potential behavior of the index may be the element of further behavior of demand and supply at the previously tested barrier of 20,000 points, which may decide whether the further downward trend will continue. Source: xStation
News:
Novartis AG (NOVN.CH) plans to invest $23 billion in the U.S. over the next five years to ensure its key medicines for Americans are produced in the country.
The investment will fund seven new facilities, including a research facility in California and six manufacturing plants, and will expand three existing facilities in the U.S., creating 1,000 jobs.
Gerresheimer (GXI.DE) shares are up 2.5% after the company reported its first-quarter results. Adjusted EBITDA from the plastics and devices business was EUR 63.4 million, compared to estimates of EUR 63.5 million. Revenue from the plastics and devices business was EUR 294.5 million, compared to expectations of EUR 284.4 million. Gerresheimer predicts organic revenue growth of 3%-5% in 2025 and an adjusted EBITDA margin of 22%.
Upgrades:
- Raiffeisen upgraded to buy at Erste Group; PT €29
K+S upgraded to hold at Stifel; PT €14.50
Downgrades:
- BP downgraded to neutral at UBS
Lanxess downgraded to sell at Goldman
HelloFresh downgraded to neutral at JPMorgan; PT €9
Other news from DAX companies. Source: Bloomberg Financial LP
The material on this page does not constitute financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other specific needs. All information provided, including opinions, market research, mathematical results and technical analyzes published on the Website or transmitted To you by other means, it is provided for information purposes only and should in no way be construed as an offer or solicitation for a transaction in any financial instrument, nor should the information provided be construed as advice of a legal or financial nature on which any investment decisions you make should be based exclusively To your level of understanding, investment objectives, financial situation, or other specific needs, any decision to act on the information published on the Website or sent to you by other means is entirely at your own risk if you In doubt or unsure about your understanding of a particular product, instrument, service or transaction, you should seek professional or legal advice before trading. Investing in CFDs carries a high level of risk, as they are leveraged products and have small movements Often the market can result in much larger movements in the value of your investment, and this can work against you or in
